Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

May 23 2019

• By Mandy Jackson

Finance Watch — IPOs, FOPOs slowed in Q1, but VC deals soared.

Related Content

Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

May 20 2019

Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA

Apr 06 2019

Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

May 07 2019

Philogen Raises €62m To Advance Pipeline, Expand GMP Capacity

May 14 2019

Voyager Nabs Neurocrine As Partner In CNS Gene Therapy

Jan 30 2019

Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform

Jan 07 2019

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron

Jan 07 2019

Syncona Focuses On Creating Commercially Ambitious Businesses

Dec 21 2017

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Mar 22 2019

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Mar 22 2019

Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area

Mar 04 2019

Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies

Feb 18 2019

Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race

Feb 25 2019

Biogen Stays Steady As Alzheimer’s Programs Falter

Apr 24 2019

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

May 17 2019

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B

Sep 26 2018

Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture

Sep 07 2018

Vedanta Receives Cash Injection To Proceed With Microbiome-Derived Pipeline

Dec 27 2018

Asia Deal Watch: Takeda, Eisai Team With Non-Profit On Review Of Novel Targets For Antibiotics

Dec 12 2018

STORM CEO Outlines Business Model And Pipeline Goals

Apr 20 2018

Vedanta strikes deal with Janssen for IBD therapy

Jan 14 2015

Related Companies

Beam Therapeutics Inc.

Passage Bio

Adaptive Biotechnologies Corporation

Genentech, Inc.

Voyager Therapeutics, Inc

Neurocrine Biosciences, Inc.

Roche Holding AG

Spark Therapeutics, Inc.

Biogen, Inc.

Nightstar Therapeutics plc

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Verve Therapeutics, Inc.

Promethera Biosciences

Confo Therapeutics NV

Takeda Pharmaceutical Co. Ltd.

Phathom Pharmaceuticals, Inc.

Philogen S.p.A.

Schrodinger, Inc.

Nimbus Therapeutics, Inc.

Morphic Therapeutic, Inc.

WuXi AppTec

Redona Therapeutics

CinCor Pharma, Inc.

Vedanta Biosciences, Inc.

STORM Therapeutics Ltd

Additional Topics

Financing Regenerative Medicine StartUps and SMEs Business Strategies Gene Therapy Commercial BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window